JPMorgan upgrades Biogen rating and sets price target at $300
JPM JPMorgan Chase & Co
$334.30 +0.39%
View chart & analysis → - 1JPMorgan upgraded Biogen's investment rating from Neutral to Overweight.
- 2Felzartamab's market value is expected to exceed $2 billion in cases of antibody-mediated rejection.
- 3JPMorgan set a price target of $300 per share for December 2027.
So what's the key point?
JPMorgan recommended buying more Biogen stock. They expect the stock price to reach $300 because the company's medicine is expected to have significant market value.
Source Investing.com · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.